Topics

MAX 10181 Given Orally to Patients With Advanced Solid Tumor

2019-10-15 11:10:48 | BioPortfolio

Summary

This is a multi-center, first-in-human, non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-10181 in patients with advanced solid tumor.

Description

Currently, immunotherapy of PD-1/L1 inhibition is gaining the leadership role due to its durable response to some tumors and low occurrence of side effects. Since the current FDA approved anti-PD-1/L1 antibodies work for only 20-30% of the patients.

MAX-10181 is orally active with activity similar to FDA approved antibody Durvalumab. In combination study, it improved the therapeutic efficacy for both anti-PD-L1 Durvalumab and anti-PD-1 Nivolumab. It also penetrates BBB for potential use in brain tumor. More importantly, it demonstrated excellent safety profile in rats and dogs.

These attributes support further studies in human clinical trials.

Study Design

Conditions

Solid Tumor

Intervention

MAX-10181

Status

Not yet recruiting

Source

Maxinovel Pty., Ltd.

Results (where available)

View Results

Links

Published on BioPortfolio: 2019-10-15T11:10:48-0400

Clinical Trials [2158 Associated Clinical Trials listed on BioPortfolio]

ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors

RATIONALE: ABT-510 and bevacizumab may stop the growth of solid tumors by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ...

A Study of MORAb-003 in Patients With Solid Tumor

MORAb-003 is intravenously administered to Japanese patients with a folate receptor alpha-expressing solid tumor in order to investigate dose-limiting toxicity and estimate maximum tolerat...

A Study of AK-01 in Solid Tumors

This two-part study consists of a Phase 1 dose escalation study in participants with locally advanced or metastatic solid tumors, and a Phase 2 portion in up to 3 cohorts with either Small...

A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors

This is a single center、single arm、open-label, to investigate the safety and efficacy of PD-1 and DC-CIK with anti-solid tumor

Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria ...

PubMed Articles [8835 Associated PubMed Articles listed on BioPortfolio]

Luteolin and 5-flurouracil act synergistically to induce cellular weapons in experimentally induced Solid Ehrlich Carcinoma: Realistic role of P53; a guardian fights in a cellular battle.

Solid Ehrlich Carcinoma (SEC) is an undifferentiated tumor used in tumor studies and chemotherapy investigations.

Solid pseudopapillary tumor of the pancreas in a 17-year-old girl.

Solid pseudopapillary tumor of the pancreas is a rare tumor of low malignant potential. The aim of this paper is to present and discuss a case of solid pseudopapillary tumor of the pancreas occurring ...

Repolarization of M2 to M1 macrophages triggered by lactate oxidase released from methylcellulose hydrogel.

Deregulated proliferation of tumor is generally associated with altered energy metabolism. A high rate of anaerobic glycolysis in solid tumors contributes to an acidification of pH to ~6.7-7.2 in the ...

Differential risk of severe infection in febrile neutropenia among children with blood cancer or solid tumor.

To describe and analyze the differences between infections in children with febrile neutropenia (FN) treated for solid tumor or blood cancer.

Evaluating the tumor biology of lung adenocarcinoma: A multimodal analysis.

We evaluated the relationships among functional imaging modality such as PET-CT and DW-MRI and lung adenocarcinoma pathologic heterogeneity, extent of invasion depth, and tumor cellularity as a marker...

Medical and Biotech [MESH] Definitions

A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.

A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)

A solid tumor consisting of a dense infiltration of MAST CELLS. It is generally benign.

An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.

A smooth, solid or cystic fibroepithelial (FIBROEPITHELIAL NEOPLASMS) tumor, usually found in the OVARIES but can also be found in the adnexal region and the KIDNEYS. It consists of a fibrous stroma with nests of epithelial cells that sometimes resemble the transitional cells lining the urinary bladder. Brenner tumors generally are benign and asymptomatic. Malignant Brenner tumors have been reported.

More From BioPortfolio on "MAX 10181 Given Orally to Patients With Advanced Solid Tumor"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...


Searches Linking to this Trial